FDA approves HIV drug for adults who are resistant, intolerant of other treatments

The FDA announced approval of lenacapavir, a new antiretroviral medication for adults with HIV type 1 who cannot be treated with other therapies because of resistance, intolerance or safety concerns.
According to an FDA press release, lenacapavir (Sunlenca, Gilead Sciences) is the first among a new class of drugs — capsid inhibitors — to receive approval for treating HIV-1. The drug initially is administered via oral tablets and subcutaneous injections, followed by maintenance injections every 6 months. It can be given in combination with other antiretroviral medications.
“Today’s

The FDA announced approval of lenacapavir, a new antiretroviral medication for adults with HIV type 1 who cannot be treated with other therapies because of resistance, intolerance or safety concerns.
According to an FDA press release, lenacapavir (Sunlenca, Gilead Sciences) is the first among a new class of drugs — capsid inhibitors — to receive approval for treating HIV-1. The drug initially is administered via oral tablets and subcutaneous injections, followed by maintenance injections every 6 months. It can be given in combination with other antiretroviral medications.
“Today’s